Mark Sullivan

Mark Sullivan is a clinical and regulatory scientist with comprehensive experience of the development of new medicines for infectious diseases. He is the founder and CEO/Managing Director of Medicines Development for Global Health (MDGH). He has led global cross functional project teams, regulatory interactions (including peri- and post-application), and has personally run and/or had responsibility for over 100 clinical trials at all stages of development. Mark was project leader for moxidectin through FDA approval and has a broad therapeutic experience in infectious diseases, and particularly hepatitis B, hepatitis C, HIV, onchocerciasis, lymphatic filariasis, scabies, the soil transmitted helminths, Hansen’s disease and TB. He is an Honorary Professor at the University of New South Wales and an Officer of the Order of Australia.